Literature DB >> 8482564

Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides.

J M Watson1, J S Berek, O Martínez-Maza.   

Abstract

In previous work, we saw that interleukin-6 (IL-6), a multifunctional cytokine, is produced by epithelial ovarian cancer cells and that ovarian cancer cells express the IL-6 receptor. Here, we examined the possibility that IL-6 acts as an autocrine growth factor for ovarian cancer cells. Inhibition of IL-6 gene expression by exposure to IL-6 antisense oligonucleotides resulted in greatly decreased cellular proliferation. Exposure of ovarian cancer cell lines (CAOV-3, OVCAR-3, and OC-436), to 1-5 microM of a 15-base single-stranded antisense IL-6 oligodeoxynucleotide, specific for a sequence in the second coding exon of the IL-6 gene, resulted in decreased IL-6 production and a > 80-85% inhibition of cellular proliferation. However, the addition of exogenous IL-6 failed to restore the proliferation of the antisense-treated cells. Antibodies to IL-6 did not consistently inhibit cell growth nor did rIL-6 enhance precursor frequency in a limiting dilution analysis. These results suggest that IL-6 does not directly induce the proliferation of ovarian cancer cells although endogenous IL-6 production is needed for optimal cell growth. As the majority of epithelial ovarian cancers produce IL-6, the direct specific inhibition of IL-6 gene expression is of potential therapeutic value.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482564     DOI: 10.1006/gyno.1993.1077

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma.

Authors:  Ruchi Garg; Melissa Wollan; Vijaya Galic; Rochelle Garcia; Barbara A Goff; Heidi J Gray; Elizabeth Swisher
Journal:  Gynecol Oncol       Date:  2006-10-04       Impact factor: 5.482

2.  Interleukin-6 (IL-6) production in carcinoma of the cervix.

Authors:  H Takano; K Harigaya; G Ishii; Y Sugaya; S Soeta; T Nunoyama; H Shirasawa; K Shimizu; H Tokita; B Simizu; A Mikata; S Sekiya
Journal:  Arch Gynecol Obstet       Date:  1996       Impact factor: 2.344

3.  Macrophage colony-stimulating factor is expressed by an ovarian carcinoma subline and stimulates the c-myc proto-oncogene.

Authors:  G Krupitza; R Fritsche; E Dittrich; H Harant; H Huber; T Grunt; C Dittrich
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

4.  Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer.

Authors:  G Scambia; U Testa; P Benedetti Panici; E Foti; R Martucci; A Gadducci; A Perillo; V Facchini; C Peschle; S Mancuso
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

5.  Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.

Authors:  Samar Masoumi-Moghaddam; Afshin Amini; Ai-Qun Wei; Gregory Robertson; David L Morris
Journal:  J Ovarian Res       Date:  2015-08-19       Impact factor: 4.234

Review 6.  Therapeutic targets and new directions for antibodies developed for ovarian cancer.

Authors:  Heather J Bax; Debra H Josephs; Giulia Pellizzari; James F Spicer; Ana Montes; Sophia N Karagiannis
Journal:  MAbs       Date:  2016-08-05       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.